✦ LIBER ✦

608 Phase I Dose-escalation Trial of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B), Combined with an mTOR Inhibitor, Temsirolimus, in Patients with Advanced Solid Tumors

✍ Scribed by Naing, A.; Mita, M.; Komarnitsky, P.; Milner, A.; von Richter, O.; Ogden, J.; Piha-Paul, S.; Fu, S.; Asatiani, E.; Kurzrock, R.

Book ID: 123058424
Publisher: Elsevier Science
Year: 2012
Tongue: English
Weight: 64 KB
Volume: 48
Category: Article
ISSN: 0959-8049
DOI: 10.1016/S0959-8049(12)72405-X

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

600 Pharmacokinetics and Pharmacodynamic

600 Pharmacokinetics and Pharmacodynamics of a Selective Oral MEK1/2 Inhibitor, Pimasertib (MSC1936369B/AS703026), in Patients with Advanced Solid Tumors

✍ Houédé, N.; Delord, J.P.; Awada, A.; Lebbe, C.; Lesimple, T.; Schellens, J.H.M.; 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 58 KB

Phase Ib/II, open-label, dose-escalation

Phase Ib/II, open-label, dose-escalation study of LGX818, an oral selective BRAF inhibitor, in combination with MEK162, an oral MEK1/2 inhibitor, in patients with BRAF V600-dependent advanced solid tumors: preliminary results

✍ Kefford, Richard; Sullivan, Ryan J; Miller, Wilson H; Elez, Elena M; Tan, Daniel 📂 Article 📅 2014 🏛 BioMed Central 🌐 English ⚖ 91 KB

Phase I, Dose-Escalation Study of BKM120

Phase I, Dose-Escalation Study of BKM120, an Oral Pan-Class I PI3K Inhibitor, in Patients With Advanced Solid Tumors

✍ Bendell, J. C.; Rodon, J.; Burris, H. A.; de Jonge, M.; Verweij, J.; Birle, D.; 📂 Article 📅 2012 🏛 American Society of Clinical Oncology 🌐 English ⚖ 196 KB

366 Phase I Dose-escalation Study of the

366 Phase I Dose-escalation Study of the Oral Dual MTOR/PI3K Inhibitor BEZ235, Solid Dispersion System (SDS) Sachet Formulation, in Patients with Advanced Solid Tumors

✍ Ahnert, J. Rodon; Burris, H.A.; Schellens, J.H.M.; Schuler, M.; Goodman, O.; Bri 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 62 KB

1243 Phase I dose-escalation study of co

1243 Phase I dose-escalation study of continuous oral treatment with the angiokinase inhibitor BIBF 1120 in patients with advanced solid tumors

✍ H. Kaneda; I. Okamoto; T. Satoh; T. Arao; K. Nishio; A. Sarashina; K. Konishi; P 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 53 KB

Phase I dose-escalation and -expansion s

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

✍ Rodon, Jordi; Braña, Irene; Siu, Lillian L; Jonge, Maja J; Homji, Natasha; Mills 📂 Article 📅 2014 🏛 Springer US 🌐 English ⚖ 925 KB